Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TXMD
TXMD logo

TXMD Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
2.306
Open
2.290
VWAP
2.30
Vol
277.00
Mkt Cap
26.51M
Low
2.290
Amount
637.36
EV/EBITDA(TTM)
--
Total Shares
11.57M
EV
19.39M
EV/OCF(TTM)
9.25
P/S(TTM)
9.47
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
Show More

Events Timeline

(ET)
2025-11-12
16:14:37
TherapeuticsMD Announces Q3 Earnings Per Share of 0c Compared to (5c) Last Year
select
2025-08-12 (ET)
2025-08-12
16:36:09
TherapeuticsMD reports Q2 EPS 5c vs. (9c) last year
select
2025-05-13 (ET)
2025-05-13
16:13:37
TherapeuticsMD reports Q1 EPS (6c) vs. (7c) last year
select

News

NASDAQ.COM
9.5
01-08NASDAQ.COM
ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept
  • Clinical Trial Progress: ALX Oncology Holdings Inc. announced positive data from its Phase 2 trial of evorpacept for indolent B-cell non-Hodgkin lymphoma, leading to a 10.17% stock increase to $1.30, with detailed results set to be presented at the ASH Annual Meeting on December 7, 2025, potentially boosting investor confidence.
  • Sales Performance Surge: Globus Medical, Inc. reported preliminary unaudited Q4 2025 sales of approximately $823.2 million, a 25.2% year-over-year increase, with full-year sales expected to reach $2.936 billion, reflecting strong performance and growth potential in the medical device market.
  • Future Outlook: Globus Medical set its 2026 revenue guidance between $3.18 billion and $3.22 billion, with projected non-GAAP earnings per share ranging from $4.30 to $4.40, indicating confidence in future performance that may attract more investor interest.
  • Industry Developments: Acrivon Therapeutics, Inc. plans to release clinical data updates for ACR-368 and ACR-2316 on January 8, 2026, resulting in a 6.44% stock increase to $3.14, reflecting market optimism regarding its R&D progress, which could influence future financing and partnership opportunities.
NASDAQ.COM
9.5
2025-08-13NASDAQ.COM
TherapeuticsMD Swings to Profit in Q2
  • Financial Performance: TherapeuticsMD reported a net income of $545 thousand for Q2 2025, a significant improvement from a loss of $1.05 million in the same quarter last year, driven by increased license revenue which rose to $1.0 million and a 45.5% reduction in operating expenses.

  • Business Model Transition: The company has fully transitioned to a royalty-focused business model, relying on licensing agreements with partners like Mayne Pharma for revenue, while ceasing its own research and development efforts, leading to a focus on cash preservation and operational efficiency.

NASDAQ.COM
9.5
2025-08-12NASDAQ.COM
TherapeuticsMD Q2 Earnings Summary
  • Earnings Performance: TherapeuticsMD reported earnings of $0.55 million in Q2, a significant improvement from a loss of $1.05 million in the same quarter last year.

  • Earnings Per Share (EPS): The company achieved an EPS of $0.05 in Q2, compared to a loss of $0.09 per share during the same period last year.

Benzinga
9.5
2025-03-26Benzinga
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
  • GameStop Earnings Report: GameStop Corp. shares rose 13.4% in pre-market trading after reporting fourth-quarter adjusted earnings of 30 cents per share, exceeding analyst expectations, despite revenue falling short of estimates at $1.283 billion.

  • Pre-Market Stock Movements: Several stocks saw significant gains in pre-market trading, including Theratechnologies Inc. (+88.3%) and SurgePays, Inc. (+69.5%), while others like Golden Heaven Group Holdings Ltd. (-24.4%) and Humacyte, Inc. (-22.1%) experienced notable declines.

Benzinga
4.5
2024-08-26Benzinga
TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying
  • Market Overview: The Dow Jones index rose over 450 points, indicating positive market sentiment, while insider trading activities in penny stocks reflect investor confidence or concerns regarding company prospects.

  • Recent Insider Transactions: Notable insider purchases include System1's Cee Holdings Trust acquiring shares after strong earnings, TherapeuticsMD's director buying shares following a quarterly loss, and Ault Alliance's executive purchasing shares amid dividend announcements.

Business Insider
8.4
2024-08-12Business Insider
TXMD Stock Earnings: TherapeuticsMD Reported Results for Q2 2024
  • Earnings Report: TherapeuticsMD (NASDAQ:TXMD) reported a second quarter 2024 earnings per share of -9 cents and revenue of $234,000.

  • Automated Coverage: InvestorPlace Earnings utilizes TradeSmith data to automate the reporting of quarterly earnings, providing quick access to key financial figures without human intervention.

Valuation Metrics

The current forward P/E ratio for TherapeuticsMD Inc (TXMD.O) is 10.31, compared to its 5-year average forward P/E of 0.20. For a more detailed relative valuation and DCF analysis to assess TherapeuticsMD Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.20
Current PE
10.31
Overvalued PE
10.42
Undervalued PE
-10.02

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.02
Current EV/EBITDA
0.14
Overvalued EV/EBITDA
2.22
Undervalued EV/EBITDA
-4.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.89
Current PS
2.08
Overvalued PS
8.95
Undervalued PS
-1.17

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

us stocks to up by 10% in February
Intellectia · 29 candidates
Region: USList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200One Month Rise Prob: >= 65One Month Predict Return: >= 15.0%
Ticker
Name
Market Cap$
top bottom
OVBC logo
OVBC
Ohio Valley Banc Corp
194.09M
FULT logo
FULT
Fulton Financial Corp
3.66B
IRDM logo
IRDM
Iridium Communications Inc
2.18B
SMBK logo
SMBK
SmartFinancial Inc
673.76M
RDW logo
RDW
Redwire Corp
2.12B
CURI logo
CURI
CuriosityStream Inc
214.25M

Whales Holding TXMD

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is TherapeuticsMD Inc (TXMD) stock price today?

The current price of TXMD is 2.3064 USD — it has increased 0.7

What is TherapeuticsMD Inc (TXMD)'s business?

TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).

What is the price predicton of TXMD Stock?

Wall Street analysts forecast TXMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TXMD is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is TherapeuticsMD Inc (TXMD)'s revenue for the last quarter?

TherapeuticsMD Inc revenue for the last quarter amounts to 784.00K USD, increased 43.33

What is TherapeuticsMD Inc (TXMD)'s earnings per share (EPS) for the last quarter?

TherapeuticsMD Inc. EPS for the last quarter amounts to 0.01 USD, decreased -120.00

How many employees does TherapeuticsMD Inc (TXMD). have?

TherapeuticsMD Inc (TXMD) has 1 emplpoyees as of March 25 2026.

What is TherapeuticsMD Inc (TXMD) market cap?

Today TXMD has the market capitalization of 26.51M USD.